Manufacturing Facilities
Delivering high quality products across the globe
11 manufacturing facilities across 4 countries
Monroe, US
Spread across 100,000 sq.ft., this facility will manufacture oral solids, injectable and nebulized products.
Estimated investment is approximately USD 100 Mn over 5 years.
Regulatory Approvals
- Pending for approval
Markets
USA
Annual Capacity
Oral solids: 300 - 400 Mn tablets and capsules
Injectables: 20 - 25 Mn vials and pre-filled syringes
Inhalation: 25 - 30 mn ampules
Goa, India
The facility commenced operations in 2004.
Three manufacturing facilities for production of:
- Oral – solids
- Semi-solids
- Hormones (oral solids)
ISO 14001: 2004 approved
Regulatory Approvals
- US-FDA
- TPD (Canada)
- MCC (South Africa)
- WHO – GMP
- ANVISA (Brazil)
- MHRA (UK)
Markets
North America, Western Europe
Annual Capacity
Oral solid dosages (OSD): 4000 Mn tablets and 608 Mn capsules
Semi-solids: 21 Mn tubes
Hormone: 400 Mn tablets
Baddi, India
This state-of-the-art manufacturing facility commenced operations in 2005.
The facility caters to the production of oral solids and liquid orals, external preparations like lotions, creams and respiratory segment products.
ISO 14001: 2004 approved
Regulatory Approvals
- US-FDA
- WHO-GMP
- ANVISA Brazil
- MHRA UK
- MCC South Africa
- TGA Australia
- NDA Uganda
- Ukrainian GMP
- DDA Nepal
- TPD Canada
- FDA Ghana
- CHMP Kenya
Markets
USA, Europe, India , Other semi-regulated markets for specific dosage forms
Annual Capacity
Oral solids: 800 Mn tablets / capsules
Liquids: 60 Mn bottles
External preparations: 20 Mn tubes
Respiratory segment: 15 Mn units
Nalagarh, India
The facility commenced operations in 2009.
The plant has three main sections for manufacturing liquid, ointments or creams and lotions.
ISO 14001: 2004 approved
Regulatory Approvals
- ANVISA Brazil
- NDA – Uganda
- WHO-GMP
- Local FDA
Markets
India, Asia, Africa
Annual Capacity
Oral liquids: 45 million bottles
Ointments and creams: 45 million units
Lotions: 22 million bottles
Sikkim, India
Established in 2012, the facility is focused on manufacturing oral solid dosages.
ISO 14001: 2004 approved
Regulatory Approvals
- Local FDA
Markets
India
Annual Capacity
Oral Solid dosages : 835 million tablets
Nashik, India
Glenmark’s first manufacturing unit, it began operations in 1983.
The facility manufactures products catering to demand in oral solids, liquid orals, external creams and powder shampoo.
ISO 14001: 2004 approved
Regulatory Approvals
- WHO – GMP
- ANVISA (Brazil)
- NDA – Uganda
- MOH – Nigeria
- TFDA – Tanzania
- MOH – Ethiopia
- MOH – Congo
- MCC – South Africa
- MOH – Oman
- MOH – Ukraine
- INVIMA – Columbia
Markets
Asia, India, Africa, CIS / Russia, Latin America
Annual Capacity
Oral solids: 270 Mn tablets / capsules
Oral Liquids: 27 Mn bottles
External preparations: 50 Mn units
Powder Shampoo: 20 Mn units
Indore, India
The Indore facility initiated operations in May 2009.
ISO 14001: 2004 approved
Regulatory Approvals
- US-FDA
- UK MHRA
- WHO – GMP
Markets
North America, Europe
Annual Capacity
Oral solid dosages: 1440 Mn tablets.
Buenos Aires, Argentina
The Glenmark manufacturing site at Buenos Aires, Argentina is focused on manufacturing of Oncology Injectables.
The plant is spread across 30,000 sq. ft. and it serves as a global hub for manufacturing Lyophilized and Liquid Injectables used in oncology therapies.
ISO 14001: 2004 approved
Regulatory Approvals
- US-FDA
- ANMAT Argentina
- MERCOSUR
Markets
Brazil, Latin America, India
Annual Capacity
Injectables: 3.5 Mn vials
Vysoke Myto, Czech Republic
This manufacturing facility, formerly known as Medicamenta, was set-up in 1952 and was acquired by Glenmark in 2009. Presently the facility manufactures solid-orals and semi-solids (ointments).
OHSAS certification
Regulatory Approvals
- Manufacturing licence for medicinal products (Issued by SUKL)
- Distribution licence for medicinal products (Issued by SUKL)
- Certificate of GMP Compliance of Manufacturer (Issued by SUKL)
- Certificate of GMP Compliance of a Manufacturer (Issued by USKVBL)
Markets
Czech and Slovak Republics, Poland, Romania, Hungry, Other European Union territories
Annual Capacity
Oral solid dosages: 144 Mn tablets
Ointments and creams: 1.5 Mn tubes
Aurangabad, India
Glenmark’s Aurangabad facility initiated operations in April 2012.
Aurangabad site is focused in the manufacturing Formulations (OSD, Inhaler, Foam & API). This plant is spread over 30 acres and it serves to both domestic and international markets.
ISO 14001: 2015 approved, OHSAS 18001: 2007 approved
Regulatory Approvals
- US-FDA
- UK MHRA
- WHO – GMP
- ANMAT
- ANVISA
Markets
Domestic, US, Brazil
Annual Capacity
API : Crofelemer : 1.2 MT
API : Telmisartan : 11 MT
API : Oxcarbazepine : 20 MT
Formulation : Tablet : 12 Mn
Formulation : MDI : 3.5 Mn
Formulation : DPI Device : 2 Mn
Formulation : Topical Foam : 0.6 Mn
